07.01.08
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the multiple mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans.
Published in Molecular Nutrition & Food Research, the study evaluated HMRlignan a proprietary and patent protected product developed by Hormos Medical Corporation, and manufactured and marketed by Linnea.
Several lines of evidence suggest that plant-derived dietary lignans may play a role in chemoprevention and prostate health promotion through complex pharmacological activities that may include pro- or anti-estrogenic, pro-apoptotic, antioxidant, and anti-angiogenic mechanisms.
In this new study—designed to investigate the mechanisms involved in the modulation of cell viability of the human androgen-dependent prostate cancer—LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls.
Results showed a concentration-dependent increase in the proportion of apoptotic cells for both substances; enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
For further information: 888-253-0044.
Published in Molecular Nutrition & Food Research, the study evaluated HMRlignan a proprietary and patent protected product developed by Hormos Medical Corporation, and manufactured and marketed by Linnea.
Several lines of evidence suggest that plant-derived dietary lignans may play a role in chemoprevention and prostate health promotion through complex pharmacological activities that may include pro- or anti-estrogenic, pro-apoptotic, antioxidant, and anti-angiogenic mechanisms.
In this new study—designed to investigate the mechanisms involved in the modulation of cell viability of the human androgen-dependent prostate cancer—LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls.
Results showed a concentration-dependent increase in the proportion of apoptotic cells for both substances; enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
For further information: 888-253-0044.